5-IAI

5-IAI
Clinical data
Other names	5-Iodo-2-aminoindane; 5-Iodo-2-aminoindan; 5-IAI; NRG-5
Routes of; administration	Oral
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Entactogen
ATC code	None;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act; In general: uncontrolled;
Pharmacokinetic data
Duration of action	2–4 hours
Identifiers
	IUPAC name 5-iodo-2,3-dihydro-1H-inden-2-amine;
CAS Number	132367-76-1 ;
PubChem CID	131506;
ChemSpider	116224 ;
UNII	7X16E45Y1X;
CompTox Dashboard (EPA)	DTXSID60927643 ;
Chemical and physical data
Formula	C9H10IN
Molar mass	259.090 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c2c1CC(N)Cc1ccc2I;
	InChI InChI=1S/C9H10IN/c10-8-2-1-6-4-9(11)5-7(6)3-8/h1-3,9H,4-5,11H2 ; Key:BIHPYCDDPGNWQO-UHFFFAOYSA-N ;
	(what is this?) (verify)

5-Iodo-2-aminoindane (5-IAI) is an entactogen drug of the 2-aminoindane family. Human anecdotal reports suggest that it is entactogenic but produces little euphoria or stimulation.

5-IAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It was encountered as a novel recreational designer drug in 2010, but never gained widespread popularity.